Insmed Reports Positive Phase 3b ENCORE ARIKAYCE Results

An announcement from Insmed ( (INSM) ) is now available.

On March 23, 2026, Insmed reported positive topline results from its Phase 3b ENCORE study of ARIKAYCE plus standard multidrug therapy in patients with newly occurring MAC lung infection who had not previously received antibiotics. The trial met its primary endpoint, showing a statistically significant improvement in respiratory symptom scores at Month 13, and achieved all multiplicity-controlled culture conversion endpoints, with faster and more durable bacterial clearance than placebo regimens.

The safety profile in ENCORE was consistent with known ARIKAYCE risks, with more dysphonia, cough, bronchospasm, and hypersensitivity pneumonitis in the ARIKAYCE arm but no new safety signals and no deaths attributed to treatment, while completion rates exceeded 90% in both groups. With these data, Insmed has fulfilled an FDA post-marketing requirement and plans in the second half of 2026 to seek a supplemental U.S. approval and Japanese label expansion for ARIKAYCE in MAC lung disease, potentially broadening its commercial reach and treatment role earlier in the disease course.

The most recent analyst rating on (INSM) stock is a Hold with a $148.00 price target. To see the full list of analyst forecasts on Insmed stock, see the INSM Stock Forecast page.

Spark’s Take on INSM Stock

According to Spark, TipRanks’ AI Analyst, INSM is a Neutral.

The score is held back primarily by weak financial performance (large losses and rising cash burn despite strong revenue growth and improved leverage). Offsetting this, the latest earnings call provided strong 2026 growth guidance and a credible cash runway narrative, while technical signals are mixed and valuation support is limited due to ongoing losses and no dividend.

To see Spark’s full report on INSM stock, click here.

More about Insmed

Insmed Incorporated is a global biopharmaceutical company focused on developing first- and best-in-class therapies for patients with serious and often rare diseases, including Mycobacterium avium complex (MAC) lung disease. Its lead product, ARIKAYCE (amikacin liposome inhalation suspension), is already approved for refractory MAC lung infection, and the company is targeting broader use in newly diagnosed patients in key markets such as the U.S. and Japan.

Average Trading Volume: 2,379,455

Technical Sentiment Signal: Buy

Current Market Cap: $29.32B

For an in-depth examination of INSM stock, go to TipRanks’ Overview page.